Iqirvo (Elafibranor)

Iqirvo (elafibranor) is a peroxisome proliferator-activated receptor (PPAR) agonist used as a peroxisome proliferator-activated receptor (PPAR) agonist for treating primary biliary cholangitis (PBC). It’s used in combination with ursodeoxycholic acid (UDCA) for adults who haven’t responded well to UDCA alone, or as a standalone treatment for those who can’t tolerate UDCA.

Limitations of Use: Use of this therapeutic drug is not recommended in individuals who have or develop decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy).

Recommended Dosage: The recommended dosing regimen for Iqirvo (elafibranor) is 80 mg to be taken orally once a day, with or without food. It is recommended to take this therapeutic drug at least 4 hours before or 4 hours after using a bile acid sequestrant, or at as long an interval as feasible between doses.

• Assess patients for muscle pain and myopathy before initiating treatment with Elafibranor 80 mg tablets. Consider periodic assessment (clinical exam, CPK measurement). Interrupt treatment if there is a new onset or worsening of muscle injury, or muscle pain.
• Fractures may occur in Iqirvo-treated patients. Consider the probability of fracture in the care of patients treated with Elafibranor and monitor bone health as per the current standards of care.  
• Iqirvo (elafibranor 80 mg) is not recommended during pregnancy due to potential risks to the fetus. Pregnant women should consult their healthcare provider before using this medication.
• Drug-induced liver injury (DILI) may develop in patients who took Iqirvo 80 mg once daily and patients who took it at 1.5 times the recommended dosage. Obtain baseline clinical as well as laboratory assessments before initiating treatment.
• Hypersensitivity reactions may occur with Elafibranor at 1.5 times the recommended dosage. In case of a severe hypersensitivity reaction, permanently stop treatment. If a mild or moderate hypersensitivity reaction occurs, interrupt treatment and treat promptly. Monitor the patient until signs and symptoms resolve. If a hypersensitivity reaction recurs after therapy rechallenge, then permanently stop treatment.
• Avoid the use of Iqirvo (elafibranor tablets) in patients with complete biliary obstruction. In case biliary obstruction is suspected, interrupt treatment and treat as clinically required.

What documents are required to import IQIRVO to India?

IQIRVO (elafibranor) tablets can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India

How does the order be confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
  
• Import permit if applicable

IQIRVO (elafibranor tablets) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Iqirvo in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.

IPN (Indian Pharma Network) can facilitate the supply of IQIRVO (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Iqirvo 80 mg price in India. 

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source the IQIRVO (Cancer Treatment Medicines) from across the globe and supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Iqirvo®?

Elafibranor is a Generic Name for the trade name drug Iqirvo®.

What is the Manufacturer’s Name of Iqirvo®?

Iqirvo® is manufactured by Ipsen Biopharmaceuticals, Inc.

Is Iqirvo® approved by the FDA?

Yes, Iqirvo® is approved by the FDA. Date of first approval: June 10, 2024.

What is the dosage and form of Iqirvo® supplied?

Iqirvo® is supplied as Tablets: 80 mg for oral administration. 

What are the most common side effects of Iqirvo®? 

The most common side effects of Iqirvo® are weight gain, diarrhea, abdominal pain, vomiting, arthralgia, dry mouth, nausea, constipation, muscle injury, fracture, gastroesophageal reflux disease, weight loss, and rash.

How much does Iqirvo® cost in India?

Prices may fluctuate over time due to market dynamics and regulatory changes. To obtain accurate and up-to-date information on the cost of Iqirvo 80 mg in India, it is recommended to Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Iqirvo®?

Store this oral drug at room temperature 15-30°C (59-86° F). Store in the original package (bottle and carton) to protect from light and moisture.  

Is it safe to buy Iqirvo® online in India?

Yes, one can buy Iqirvo online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in the country. We can help facilitate the supply of Iqirvo® through legal channels.